Large US retailers and online pharmacies are becoming important gateways to prescription weight-management care as demand for GLP-1 medicines grows, according to an August 1 CNBC analysis and current company programs. Amazon, Walmart and Costco now combine drug fulfillment with cash prices, virtual consultations or membership benefits, changing how some patients obtain approved obesity treatments outside traditional insurance channels.
The expansion follows US approvals of oral and injectable medicines that mimic hormones involved in appetite and blood-sugar regulation. The Associated Press reported in April that regulators approved Eli Lilly's daily orforglipron pill for obesity, joining Novo Nordisk's oral Wegovy and established injections. These are prescription treatments for eligible patients and are intended to accompany diet and physical activity, not consumer products for unsupervised use.
Amazon says its One Medical program integrates clinical weight-management support with Amazon Pharmacy and displays medication costs before an appointment. It lists insurance prices starting as low as 25 dollars a month and cash options starting at 149 dollars for some oral products, while same-day delivery reaches nearly 3,000 US cities and is planned for 4,500 by year-end. Availability and final cost depend on eligibility, dose, coverage and location.
Walmart says its Better Care Services platform connects customers with third-party virtual care, nutrition support and pharmacy fulfillment, including links to LillyDirect. Costco's member prescription program similarly advertises discounted prices on selected medicines, although conditions and membership rules apply. Together, the programs show how manufacturers, clinicians and retailers are building direct routes around persistent insurance restrictions and high list prices.
The shift may make legitimate prescriptions easier to fill and prices easier to compare, but it does not remove clinical or financial risks. Patients still require assessment for contraindications, adverse effects and ongoing monitoring, while promotional starting prices may differ from long-term costs. Retailers are also competing for recurring pharmacy relationships as treatment can continue for extended periods.
Further expansion is expected as oral medicines broaden the market and delivery networks grow. Health authorities continue to distinguish approved products dispensed through licensed pharmacies from unapproved or improperly compounded versions. For patients, the central questions remain medical suitability, reliable follow-up and the total cost over time rather than convenience alone.
Comments